U.S. FDA’s team of reviewers has requested that the regulatory advisory panel assess the requirement for additional studies on the sickle cell disease gene therapy developed by Vertex Pharmaceuticals and…
Arialys Therapeutics has secured $58 million in seed funding for the development of treatments targeting autoimmune neuropsychiatric diseases. Arialys Therapeutics, a pioneering force in neurological advancements, has secured $58 million…
2seventy bio, Inc. and JW Therapeutics, a biotech firm focusing on cell immunotherapy products, have announced their intent to broaden their strategic partnership. In a significant stride towards advancing immunotherapy,…
Seamless Therapeutics has received $12.5 million in seed funding to advance a revolutionary gene editing platform based on programmable precision designer recombinases. Seamless Therapeutics, a TU Dresden spin-off, has received…
Audentes Therapeutics has reported a third death in a clinical trial of its gene therapy against a rare genetic neuromuscular disorder. The Astellas Pharma subsidiary said it “remains committed” to…
Foldamers are sequence-specific oligomers parallel to peptides, proteins and oligonucleotides among the aim of fold up into precise three-dimensional arrangements. Configuration of foldamer is alleviated via no covalent interactions flanked…